Particularly, our findings support this hypothesis, as distinct patterns of intra-tumoral FAP expression were observed in pre-therapeutic biopsies from DLBCL and FL patients, with DLBCL showing higher FAP expression than FL—an inverse of the sFAP levels. The gene discussed is FAP; the disease is diffuse large B-cell lymphoma.